Rare tumor chemotherapy showdown: platinum vs. Non-Platinum
NCT ID NCT04365023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. The goal was to see which approach might work better for these uncommon tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
platinum chemotherapy
What this could lead to
If successful, this could help doctors choose better first-line chemotherapy for patients with these rare tumors, potentially improving survival.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove one treatment is better. The tumors are rare, making findings less generalizable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gastroenterology and digestive oncology unit - Cochin hospital
Paris, 75014, France